Mon, 25 May 2020
84
Fair in Charleston/Executive

OCALA, FL / ACCESSWIRE / February 12, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that its Chief Executive Officer, Thomas K. Equels, will appear live today as a guest on FOX Business Network's The Claman Coutdown and Cheddar's Opening Bell.

Mr. Equels is scheduled to appear on Cheddar's Opening Bell with hosts Hope King and Nora Ali at 10:20 AM ET. Mr. Equels will also appear on The Claman Countdown on the FOX Business Network with host Liz Claman between 3 PM and 4 PM ET.

Mr. Equels plans to discuss the therapeutic potential of Ampligen as both an early-onset treatment for and prophylaxis against the Wuhan coronavirus that has so far infected approximately 40,000 people and is now responsible for more deaths than the original highly pathogenic human coronavirus (SARS). Due to Ampligen's unique immune stimulation capabilities based on peer reviewed and published animal and human studies on influenza, a vaccine created by combining Ampligen and inactivated Wuhan coronavirus could potentially protect against other forms of coronavirus and future mutations of the Wuhan coronavirus.

Coronaviruses are a large family of viruses, including the deadly Severe Acute Respiratory Syndrome (SARS). After a 2002 SARS outbreak in the Guangdong province of southern China caused more than 8,000 cases and more than 800 deaths, the United States' National Institutes of Health contracted studies to evaluate potential treatments for SARS. Ampligen achieved a 100% survival rate - as compared to 100% mortality - at clinically achievable human dosage levels in SARS animal experiments.

Ampligen has generated a generally well-tolerated safety profile based on approximately 100,000 IV doses in human clinical trials to date, as well as Phase 1 safety studies in intraperitoneal (IP) and intranasal (IN) administration.

About Cheddar

Cheddar is the leading post-cable news, media, and entertainment company. Cheddar broadcasts live on SlingTV, Hulu Live, YouTube TV, Philo, Twitter, Facebook Watch, Pluto, Xumo and more. Watched live by more than 6.5M people each month, Cheddar also garners hundreds of millions of organic video views monthly across Facebook, YouTube, Twitter, Snapchat, Instagram, LinkedIn and other social & distributed video platforms. Cheddar currently broadcasts two live video news networks: Cheddar, a business news network covering the most innovative executives, founders, products, and technologies transforming our lives and economy; and Cheddar News, a fast-paced, young, non-partisan general news and headline news network. The company broadcasts from the trading floor of the New York Stock Exchange.

About The Claman Countdown

The Claman Countdown is a financial news program airing on the Fox Business Network from 3-4pm ET. Hosted by Liz Claman, this program covers the final hour of trading on Wall Street.

About AIM ImmunoTech Inc

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.

Cautionary Statement

Some of the statements included in this press release and that may be made in the Cheddar and FOX interviews may be forward-looking statements that involve a number of risks and uncertainties. For example, the filing of provisional patent applications provides no assurance that patents will ultimately be granted. No assurance can be made as to any future clinical trials related to the matter herein. No assurance can be given as to whether the current or planned trials will be successful or yield favorable data and the trials are subject to many factors including lack of regulatory approval(s), lack of study drug, or a change in priorities at the institutions sponsoring other trials. In addition, initiation of planned clinical trials may not occur secondary to many factors including lack of regulatory approval(s) or lack of study drug. Even if these clinical trials are initiated, we cannot assure that the clinical studies will be successful or yield any useful data or require additional funding. Among other things, for forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.aimimmuno.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.

Contacts:

Crescendo Communications, LLC
Phone: 212-671-1021
Email: aim@crescendo-ir.com

AIM ImmunoTech Inc
Phone: 800-778-4042
Email: IR@aimimmuno.com

SOURCE: AIM ImmunoTech Inc.



View source version on accesswire.com:
https://www.accesswire.com/576151/AIM-ImmunoTechs-CEO-to-Appear-Live-Today-on-FOX-Business-Networks-The-Claman-Countdown-and-Cheddars-Opening-Bell-to-Discuss-the-Potential-Role-of-AmpligenR-for-Use-Against-the-Wuhan-2019-Novel-Coronavirus

More South Carolina News

Access More

Sign up for South Carolina State News

a daily newsletter full of things to discuss over drinks.and the great thing is that it's on the house!